A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom

References

• Hruska KA, Methew S, Lund R, et al. Hyperphosphatemia of chronic kidney disease. Kidney Int 2008;74:148-57
   PubMed Web of Science ®Google Scholar
• Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008;52:519-30
   PubMed Web of Science ®Google Scholar
• Tonelli M, Sacks F, Pfeffer M, et al.; Cholesterol and Recurrent Events Trial Investigators. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005;112:2627-3
   PubMed Web of Science ®Google Scholar
• Dhingra R, Sullivan LM, Fox CS, et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007;167:879-85
   PubMed Web of Science ®Google Scholar
• Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005;16:520-8
   PubMed Web of Science ®Google Scholar
• Kovesdy CP, Ahmadzadeh S, Anderson JE, et al. Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int 2008;73:1296-302
   PubMed Web of Science ®Google Scholar
• Qunibi WY, Nolan CA, Ayus JC. Cardiovascular calcification in patients with end-stage renal disease: a century-old phenomenon. Kidney Int Suppl 2002 Dec;(82):S73-80
   Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention: treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009 Aug;(113):S1-130
   Google Scholar
• Steddon S, Sharples E. The UK Renal Association. Clinical Practice Guidelines: CKD-Mineral and Bone Disorders (CKD-MBD). 5th Edition (v. 6.12.10). http://www.renal.org/clinical/GuidelinesSection/Guidelines.aspx. Accessed September 2010.
   Google Scholar
• 2010 Annual Report of the Dialysis Outcomes and Practice Patterns Study: Hemodialysis Data 1999-2008. Ann Arbor, MI: Arbor Research Collaborative for Health.
   Google Scholar
• Russo D, Miranda I, Ruocco C, et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 2007;72:1255-61
   PubMed Web of Science ®Google Scholar
• Asmus HG, Braun J, Krause R, et al. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol Dial Transplant 2005;20:1653-61
   PubMed Web of Science ®Google Scholar
• Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005;68:1815-24
   PubMed Web of Science ®Google Scholar
• Chertow GM, Burke SK, Lazarus JM, et al. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 1997;29:66-71
   PubMed Web of Science ®Google Scholar
• Burke SK, Slatopolsky EA, Goldberg DI. RenaGel, a novel calcium- and aluminum-free phosphate binder, inhibits phosphate absorption in normal volunteers. Nephrol Dial Transplant 1997;12:1640-4
   PubMed Web of Science ®Google Scholar
• Guérin AP, London GM, Marchais SJ, et al. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000;15:1014-21
   PubMed Web of Science ®Google Scholar
• Goodman WG, Goldin J, Kuizon BD, et al. Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478-83
   PubMed Web of Science ®Google Scholar
• Delmez J, Block G, Robertson J, et al. A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin Nephrol 2007;68:386-91
   PubMed Web of Science ®Google Scholar
• Suki W, Zabaneh R, Cangiano J, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007;72:1130-7
   PubMed Web of Science ®Google Scholar
• Suki WN; for the Dialysis Clinical Outcomes Revisited Investigators. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial. J Renal Nutr 2008;18:91-8
   PubMed Web of Science ®Google Scholar
• Block GA, Raggi P, Bellasi A, et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007;71:438-41
   PubMed Web of Science ®Google Scholar
• Borzecki AM, Lee A, Wang SW, et al. Survival in end stage renal disease: calcium carbonate vs. sevelamer. J Clin Pharm Ther 2007;32:617-24
   PubMed Web of Science ®Google Scholar
• Taylor MJ, Elgazzar HA, Chaplin S, et al. An economic evaluation of sevelamer in patients new to dialysis. Curr Med Res Opin 2008;24:601-8
   PubMed Web of Science ®Google Scholar
• Manns B, Klarenbach S, Lee H, et al. Economic evaluation of sevelamer in patients with end-stage renal disease. Nephrol Dial Transplant 2007;22:2867-78
   PubMed Web of Science ®Google Scholar
• Huybrechts KF, Caro JJ, Wilson DA, et al. Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis. Value Health 2005;8:549-61
   PubMed Web of Science ®Google Scholar
• Huybrechts KF, Caro JJ, O'Brien JA. Prevention and management of hyperphosphatemia with sevelamer in Canada: health and economic consequences. Value Health 2009;12:16-19
   PubMedGoogle Scholar
• Ansell D, Feehally J, Feest TG, et al. UK Renal Registry Report 2007. Bristol: UK Renal Registry
   Google Scholar
• British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary (BNF) 53. http://www.bnf/org/uk/bnf/. Accessed September 2009.
   Google Scholar
• Department of Health. Reference costs 2006-07. London: DoH, 2008. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_082571. Accessed September 2009
   Google Scholar
• Dale PL, Hutton J, Elgazzar H. Utility of health states in chronic kidney disease: a structured review of the literature. Curr Med Res Opin 2008;24:193-206
   PubMed Web of Science ®Google Scholar
• Bass EB, Wills S, Fink NE, et al. How strong are patients' preferences in choices between dialysis modalities and doses? Am J Kidney Dis 2004;44:695-705
   PubMed Web of Science ®Google Scholar
• de Witt GA, Ramsteijn PG, de Charro FT. Economic evaluation of end stage renal disease treatment. Health Policy 1998;44:215-32
   PubMedGoogle Scholar
• Gorodetskaya I, Zenios S, McCulloch CE, et al. Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int 2005;68:2801-8
   PubMed Web of Science ®Google Scholar
• Manns B, Johnson JA, Taub K, et al. Quality of life in patients treated with haemodialysis or peritoneal dialysis: what are the important determinants? Clin Nephrol 2003;60:341-51
   PubMed Web of Science ®Google Scholar
• Sennfalt K, Magnusson M, Carlsson P. Comparison of haemodialysis and peritoneal dialysis – a cost-utility analysis. Peritoneal Dial Int 2002;22:39-47
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence (NICE), 2008. Guide to the methods of technology appraisal. 2008. http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf. Accessed February 2009
   Google Scholar
• Baboolal K, McEwan P, Sondhi S, et al. The cost of renal dialysis in a UK setting - a multicentre study. Nephrol Dial Transplant 2008;0:1-8
   Google Scholar
• Collins AJ, St Peter WL, Dalleska FW, et al. Hospitalization risks between Renagel phosphate binder treated and non-Renagel treated patients. Clin Nephrol 2000;54:334-41
   PubMed Web of Science ®Google Scholar